+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
APLLTD

Alembic Pharmaceuticals Share Price

₹802.80 -0.2 (-0.02%)
26.27% Gain from 52W Low

03 Nov, 2026 3:50 PM (IST)

Alembic Pharmaceuticals live price: ₹802.80. It opened at ₹803 vs previous close ₹803; intraday high/low: ₹815/₹799. The 50 & 200 DMA stand at ₹806.10/₹810.70.

Alembic Pharmaceuticals Performance

  • Today's Low
  • ₹799
  • Today's High
  • ₹815
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹998
  • Open Price₹803
  • Previous Close₹803
  • Volume94,627
  • 50 DMA₹806.10
  • 100 DMA₹804.50
  • 200 DMA₹810.70

Alembic Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -1.53%
  • Over 3 Month + 0.72%
  • Over 6 Month + 6.33%
  • Over 1 Year -10.54%

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Invest Now

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.8
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 15,780
  • P/B Ratio
  • 2.7
  • Average True Range
  • 21
  • EPS
  • 35.3
  • Dividend Yield
  • 1.5
  • MACD Signal
  • -7.2
  • RSI
  • 51.37
  • MFI
  • 72.59

Latest Stock News Updates

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Updated link for the Post Results Conference Call

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Please find enclosed intimation for Investor Call re-scheduled on 4th November, 2026.

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Venetoclax Tablets, 10mg, 50 mg and 100 mg.

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹802.80
-0.2 (-0.02%)
pointer
  • Bearish Moving Average 6
  • Bullish Moving Average 10
  • 20 Day
  • ₹796.40
  • 50 Day
  • ₹806.10
  • 100 Day
  • ₹804.50
  • 200 Day
  • ₹810.70

Resistance and Support

805.37 Pivot Speed
  • R3 828.60
  • R2 821.70
  • R1 812.30
  • S1 795.90
  • S2 789.00
  • S3 779.60

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-11-04 Quarterly Results
2026-08-04 Quarterly Results
2026-05-15 Audited Results & Final Dividend
2026-02-05 Quarterly Results
2025-11-04 Quarterly Results & Others To consider other business matters.
Date Purpose Remarks
2026-07-29 FINAL Rs.12.00 per share(600%)Final Dividend
2025-07-29 FINAL Rs.11.00 per share(550%)Final Dividend
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)
View Alembic Pharmaceuticals Dividend History Arrow

Alembic Pharmaceuticals Shareholding Pattern

69.87%
10.16%
8.5%
6.94%
4.55%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. View More
  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • ISIN
  • INE901L01018

Similar Stocks to Alembic Pharmaceuticals

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹802 As on 03 November, 2026 | 22:18

The Market Cap of Alembic Pharmaceuticals is ₹15780.1 Cr As on 03 November, 2026 | 22:18

The P/E ratio of Alembic Pharmaceuticals is 22.8 As on 03 November, 2026 | 22:18

The PB ratio of Alembic Pharmaceuticals is 2.7 As on 03 November, 2026 | 22:18

The 52 week High & Low of Alembic Pharmaceuticals is ₹998/₹635.8 respectively As on 03 November, 2026 | 22:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23